More than three-quarters of lupus patients taking obinutuzumab (Gazvya) had a significant improvement in their symptoms after a year on the drug, researchers reported March 6 in The New England ...

Drug-induced lupus is more common in men because they are given these drugs more often; however, not everyone who takes these drugs will develop the disease. Specific criteria for diagnosing ...

Phase III results put obinutuzumab in line for approval ...

Nipocalimab has been granted U.S. Food and Drug Administration Fast Track designation as a potential treatment for adults with systemic lupus erythematosus (SLE). Fast Track designation is designed to ...

“The European approval of Benlysta represents a significant milestone, and we are very pleased to be able to provide physicians an additional therapeutic option for treating appropriate patients with ...

In patients with systemic lupus erythematosus (SLE) who had been in remission for at least 1 year, immunosuppressant withdrawal was noninferior to glucocorticoid withdrawal, with no significant ...

Finally there's a bit of good news in the long search for a viable treatment. Lupus is an autoimmune disease in which the body's immune system attacks healthy, normal tissue. It mainly strikes women ...

The Wall Street Journal is reporting that the Food and Drug Administration approved a new lupus drug from Human Genome Sciences Inc. and GlaxoSmithKline PLC, marking the first new treatment for the ...

For the millions of people living with lupus – a chronic autoimmune disease that can damage the kidneys, brain and other ...

New York, NY - While there have certainly been some bumps in the road during recent weeks, some targeted SLE therapies in the pipeline still show tremendous promise, according to Dr Joan T Merrill ...